IP Library › Granted Patent US 7,417,063
Granted Patent B2
US 7,417,063 · App. 11/103,139 · Granted Aug 26, 2008

Bicyclic heterocycles useful as serine protease inhibitors

Assignee: Bristol-Myers Squibb Company
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,417,063
App. No.
11/103,139
Granted
Aug 26, 2008
Kind
B2
Abstract

The present invention provides compounds of Formula (I): or a stereoisomer or pharmaceutically acceptable salt or solvate form thereof, wherein the variables A, B, L 1 , L 2 , X 1 , X 2 , X 3 , X 4 , X 5 , R 4 , and W are as defined herein. The compounds of Formula (I) are useful as selective inhibitors of serine protease enzymes of the coagulation cascade and/or contact activation system; for example thrombin, factor Xa, factor XIa, factor IXa, factor VIIa and/or plasma kallikrein. In particular, it relates to compounds that are selective factor XIa inhibitors. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating thromboembolic and/or inflammatory disorders using the same.

Claims (144)

1. A compound of Formula (Ic):

or a stereoisomer or a pharmaceutically acceptable salt or a solvate thereof, wherein:

L 1 is —CH 2 ;

L 2 is a bond;

A is phenylene substituted with 0-2 R 11 , or pyridylene substituted with 0-2 R 11 ;

provided that the groups L 1 and L 2 are attached to said phenylene or heteroaryl in a ortho- or meta-orientation;

B is phenyl substituted with 0-2 R 11 and 0-1 R 12 , a 5- to 6-membered heterocycle substituted with 0-2 R 11 and 0-1 R 12 and selected from: pyrrolidinyl, pyrrolyl, pyrrolinyl, pyrazolyl, oxazolyl, imidazolyl, imidazolinyl, pyrazolyl, pyrazolinyl, isoxazolyl, isothiazolyl, triazolyl, tetrazolyl, pyranyl, piperidyl, piperazinyl, pyridyl, pyrimidinyl, pyrazinyl, and triazinyl;

X 5 is CH or N;

R 1 is —C(═NH)NH 2 , —C(═NOH)NH 2 , —CONH 2 , —CH 2 NH 2 , or —C(O)NR 7a R 8 ;

R 4 is H, —(CH 2 ) r —CONR 7a R 8 , C 1-4 alkyl, —(CH 2 ) r —C 3-7 cycloalkyl, —(CH 2 ) r -phenyl, or —(CH 2 ) r -5- to 6-membered heteroaryl selected from: pyrrolyl, pyrazolyl, oxazolyl, thiazolyl, imidazolyl, isoxazolyl, isothiazolyl, triazolyl, tetrazolyl, pyridazinyl, pyridyl, pyrimidinyl, pyrazinyl, and triazinyl;

R 7 is, independently at each occurrence, H, C 1-6 alkyl, or benzyl;

R 7a is, independently at each occurrence, H, C 1-4 alkyl substituted with 0-1 R 7a or 0-1 R 7c , C 3-7 cycloalkyl substituted with 0-2 R f , phenyl substituted with 0-3 R f , or a 5-6 membered heterocycle comprising: carbon atoms and 1-4 heteroatoms selected from N, O, and S(O) p , and substituted 0-3 R f ;

R 7b is ═O , OR g , F, Cl, Br, I, CN, NO 2 , —NR 7 R 8 , —C(O)R g , —CO 2 R g , —NR 8 C(O)R g , —CONR 8 R 9 , —NR 8 C(O)NR 8 R 9 , —SO 2 NR 8 R 9 , —NR 8 SO 2 NR 8 R 9 , —NR 8 SO 2 -C 1-4 allyl, —NR 8 SO 2 CF 3 , —NR 8 SO 2 -phenyl, —S(O) 2 CF 3 , —S(O) p —C 1-4 alkyl, —S(O) p -phenyl, or —(CF 2 ) r CF 3 ;

R 7c is C 3-10 carbocycle substituted with 0-3 R f or a 5-12 membered heterocycle comprising: carbon atoms and 1-4 heteroatoms selected from N, O, and S(O) p , and substituted 0-3 R f ;

R 8 is, independently at each occurrence, H, C 1-6 alkyl, or benzyl;

R 9 is, independently at each occurrence, H, C 1-6 alkyl, or benzyl;

R 10 is, independently at each occurrence, H, C 1-6 alkyl substituted with 0-2 R 10a , C 2-6 alkenyl substituted with 0-2 R 10a , C 2-6 alkynyl substituted with 0-2 R 10a , (CH 2 ) r C 3-10 carbocycle substituted with 0-3 R 10b , or —(CH 2 ) r -5-10 membered heterocycle comprising: carbon atoms and 1-4 heteroatoms selected from N, O, and S(O) p , and substituted with 0-3 R 10b ;

R 10a is, independently at each occurrence, H, C 1-4 alkyl, OR a , F, ═O, CF 3 , CN, NO 2 , —C(O)R a , —CO 2 R a , —CONR 7a R 8 , or —S(O) p R c ;

R 10b is, independently at each occurrence, H, ═O , OR a , F, Cl, Br, I, CN, NO 2 , —NR 7 R 8 , —C(O)R a , —CO 2 R a , —NR 8 C(O)R a , —CONR 7a R 8 , —SO 2 NR 8 R 9 , —NR 8 SO 2 NR 8 R 9 , —NR 8 SO 2 -C 1-4 alkyl, —NR 8 SO 2 CF 3 , —NR 8 SO 2 -phenyl, —S(O) 2 CF 3 , —S(O) p —C 1-4 alkyl, —S(O) p -phenyl, —(CF 2 ) r CF 3 , C 1-4 alkyl substituted with 0-2 R e , C 2-4 alkenyl substituted with 0-2 R e , or C 2-4 alkynyl substituted with 0-2 R e ;

R 11 is, independently at each occurrence, H, F, Cl, CF 3 , C 1-6 alkyl, —(CH 2 ) r —OR a , CN, —CH 2 ) r NR 7 R 8 , —(CH 2 ) r —C(═NR 8 )NR 7 R 9 , —C(O)R a , —CO 2 R a , —(CH 2 ) r NR 8 C(O)R a , —NR 8 C(O)OR c , —CONR 7a R 8 , —NR 8 C(O)NR 8 R 10 , —SO 2 NR 8 R 10 , —NR 8 SO 2 NR 8 R 10 , or —NR 8 SO 2 —C 1-4 alkyl;

R 12 is —CONR 7a R 8 , —(CH 2 ) r CO 2 R 12a , —CH 2 OR 12a , —SO 2 NHCO 2 R 12a , —CONHSO 2 R 12b , —NHSO 2 R 12b , —SO 2 NHCO 2 R 12a , —CONHSO 2 R 12b , —NHSO 2 R 12b , or —(CH 2 ) r -5-tetrazolyl;

R 12a is, independently at each occurrence, H or C 1-6 alkyl;

R 12b is, independently at each occurrence, C 1 -C 4 alkyl substituted with 0-1 R 12 c, C 2 -C 4 alkenyl substituted with 0-1 R 12c , C 2 -C 4 alkynyl substituted with 0-1 R 12c , —CH 2 ) r C 3 C 7 carbocycle substituted with 0-2 R 12c , or —(CH 2 ) r -5-6 membered heterocycle comprising: carbon atoms and 1-4 heteroatoms selected from N, O, and S(O) p , and substituted with 0-2 R 12c ;

R 12c is, independently at each occurrence, H, F, Cl, Br, I, CF 3 , OCF 3 , CN, NO 2 , OR a , —CO 2 R a , —NR 7 R 8 , —SO 2 R c , C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, —(CH 2 ) r -C 3-10 carbocycle substituted with 0-3 R d ; or —(CH 2 ) r -5-10 membered heterocycle comprising: carbon atoms and 1-4 heteroatoms selected from N, O, and S(O) p , and substituted with 0-3 R d ;

R a is, independently at each occurrence, H, C 1-4 alkyl, —(CH 2 ) r -C 3-7 cycloalkyl, —CH 2 ) r C 6-10 aryl, or —(CH 2 ) r -5-10 membered heteroaryl, wherein said aryl or heteroaryl groups are optionally substituted with 0-2 R f ;

R c is, independently at each occurrence, C 1-4 alkyl, phenyl or benzyl;

R d is, independently at each occurrence, H, ═O, OR a , F, Cl, Br, I, CN, NO 2 , —NR 7 R 8 , —C(O)R a , —CO 2 R a , —NR 8 C(O)R a , —CONR 7a R 8 , —SO 2 NR 8 R 10 , —NR 8 SO 2 NR 8 R 10 , —NR 10 SO 2 —C 1-4 alkyl, —NR 10 SO 2 CF 3 , —NR 10 SO 2 -phenyl, —S(O) 2 CF 3 , —S(O) p -C 1-4 alkyl, —S(O) p phenyl, —(CF 2 ) r CF 3 , C 1-6 alkyl substituted with 0-2 R a , C 2-6 alkenyl substituted with 0-2 R e , or C 2-6 alkynyl substituted with 0-2 R e ;

R e is, independently at each occurrence, ═O, OR a , F, Cl, Br, I, CN, NO 2 , —NR 8 R 9 , —C(O)R a , —CO 2 R a , —NR 8 C(O)R a , —CONR 7a R 8 , —SO 2 NR 8 R 9 , —NR 8 SO 2 NR 8 R 9 , —NR 8 SO 2 -C 1-4 alkyl, —NR 8 SO 2 CF 3 , —NR 8 SO 2 -phenyl, —S(O) 2 CF 3 , —S(O) p -C 1-4 alkyl, —S(O) p phenyl, or —(CF 2 ) r CF 3 ;

R f is, independently at each occurrence, H, ═O, —(CH 2 ) r OR g , F, Cl, Br, CF 3 , CN, NO 2 , —NR 8 R 9 , —C(O)R a , —C(O)OR a , —NR 8 C(O)R a , —C(O)NR 8 R 9 , —SO 2 NR 8 R 9 , -NR 8 SO 2 -C 1-4 alkyl, —NR 8 SO 2 CF 3 , —S(O) 2 CF 3 , —S(O) p -C 1-4 alkyl, C 1 -C 6 alkyl, C 2 -C 6 alkenyl, or C 2 -C 6 alkynyl;

R g is, independently at each occurrence, H or C 1-4 alkyl;

p, at each occurrence, is selected from 0, 1, and 2; and

r, at each occurrence, is selected from 0, 1, 2, 3, and 4.

2. A compound according to claim 1 , wherein:

B is phenyl substituted with 0-2 R 11 and 0-1 R 12 , pyridyl substituted with 0-2 R 11 and 0-1 R 12 , pyrrolidinyl substituted with 0-2 R 11 and 0-1 R 12 , pyrazolyl substituted with 0-2 R 11 and 0-1 R 12 , or piperidyl substituted with 0-2 R 11 and 0-1 R 12 ;

R 1 is —C(═NH)NH 2 , —C(═NOH)NH 2 , —CONH 2 , or —CH 2 NH 2 ;

R 11 is, independently at each occurrence, H, F, Cl, OH, OMe, CN, Me, Et, Pr, i-Pr, Bu, i-Bu, t-Bu, —NH 2 , —CH 2 OH, —CO 2 H, —CO 2 Me, —CO 2 Lt, —CONH 2 , —NHCOMe, —NHCOEt, —NHCOPr, —NHCO(i-Pr), —NHCO(i-Bu), —CONHMe, —CONHEt, —CONHPr, —CONH(i-Bu), —CONHCH 2 CONH 2 , —CONHCH 2 CONHMe, —CONHCH 2 CONHEt, —CONH(—CH 2 -cyclopropyl), —CONH(—CH 2 -cyclohexyl), —CONHBn, —CONH(—CH 2 -2-oxazolyl), —CONH(—CH 2 -1,2,4-triazolyl), —CONH(—CH 2 -2-pyridyl), —CONH(-(CH 92 -2-pyridyl), —CONH(—CH 2 -3-pyridyl), —CONH(—CH 2 -4-pyridyl), —CONH(—CH 2 -2-pyrimidinyl), —CONH(—CH 2 -3,4,5,6-tetrahydro-2-pyrimidinyl), —CONH(—CH 2 -(5-Me-2-pyrazinyl)), —SO 2 NH 2 , or —CONHSO 2 Me; and

R 12 is —OH, —OMe, —CH 2 OH, —CO 2 H, —CH 2 (CO 2 H), —CO 2 Me, —CO 2 Et, —SO 2 NH 2 , or —CONH 2 .

3. A compound of Formula (Id):

or a stereoisomer or a pharmaceutically acceptable salt or solvate thereof, wherein:

L 1 is —CH 2 ;

L 2 is a bond;

A is 1,2-phenylene, 5-CO 2 H-1,2-phenylene, 5-CONHMe-1,2-phenylene, 5-CONHEt-1,2-phenylene, 5-CONHPr-1,2-phenylene, 5-CONHBn-1,2-phenylene, 5-CONHCH 2 CONH 2 -1,2-phenylene, 5-CONHCH 2 CONHMe-1,2-phenylene, 5-CONHCH 2 CONHLt-1,2-phenylene, 5-CONH(—CH 2 -cyclopropyl)-1,2-phenylene, 5-CONH-(—CH 2 -cyclohexyl)-1,2-phenylene, 5-CONH-(—CH 2 -(4-COMe-Ph))-1,2-phenylene, 5-CONH(—CH 2 -2-oxazolyl)-1,2-phenylene, 5-CONH(—CH 2 -1,2,4-triazolyl)-1,2-phenylene, 5-CONH(—CH 2 -2-pyridyl)-1,2-phenylene, 5-CONH(—CH 2 -3-pyridyl)-1,2-phenylene, 5-CONH(—CH 2 -4-pyridyl)-1,2-phenylene, 5-CONH(—CH 2 -2-pyrimidinyl)-1,2-phenylene, 5-CONH(—CH 2 -3,4,5,6-tetrahydro-2-pyrimidinyl)-1,2-phenylene, 5-CONH(—CH 2 -(5-Me-2-pyrazinyl)-1,2-phenylene, 5-CONH(—CH 2 -2-thiazolyl)-1,2-phenylene, S —CONH(—CH 2 -4-thiazolyl)-1,2-phenylene, 5-CONH(—CH 2 -5-thiazolyl)-1,2-phenylene, 5-CONH(—CH 2 -2-imidazolyl)-1,2-phenylene, 5-CONH(—CH 2 -4-imidazolyl)-1,2-phenylene, 5-NHCOMe-1,2-phenylene, 5-NHCO(i-Bu)-1,2-phenylene, 1,3-phenylene, 5-NHCOMe-1,3-phenylene, 5-NHCOEt-1,3-phenylene, or 5-NHCOPr-1,3-phenylene, wherein the attachment to L 2 is at carbon 1 of said phenylene groups;

B is 2-CO 2 H-phenyl, 2-CO 2 Et-phenyl, 2-CONH 2 -phenyl, 2-CONHSO 2 Me-phenyl, 2-SO 2 NH 2 -phenyl, 2-CH 2 OH-4-OMe-phenyl, 2-CO 2 H-3-Me-phenyl, 2-CO 2 H-4-Me-phenyl, 2-COY-S -Me-phenyl, 2-CO 2 Et-4-Me-phenyl, 2-CO 2 H-4-Cl-phenyl, 2-CO 2 Et-4-Cl-phenyl, 2-CO 2 H-4-OMe-phenyl, 2-CO 2 Et-4-OMe-phenyl, 2-CO 2 H-4-CONH 2 -phenyl, 2-CO 2 H-4,5-methylenedioxyphenyl, 3-CO 2 H-6-Me-2-pyridyl, 3-CO 2 H-5-Cl-2-pyridyl, 2-CO 2 H-1-pyrrolidinyl, 2-CO 2 Et-1-pyrrolidinyl, 1-Me-3-CO 2 H-4-pyrazolyl, 1-Me-5-CO 2 H-4-pyrazolyl, or 2-CO 2 H-1-piperidyl;

X 5 is CH or N;

R 1 is —C(═NH)NH 2 or —C(═NOH)NH 2 ; and

R 4 is H, Me, Et, Pr, i-Bu, Bn, —CONH 2 , —(CH 2 ) 2 CONH 2 , —(CH 2 ) 3 CONH 2 , —SO 2 Me, —CH 2 -cyclopropyl, or —CH 2 -3-pyridyl.

4. A compound according to claim 3 , wherein:

A is 1,2-phenylene, 5-CO 2 H-1,2-phenylene, 5-CONHMe-1,2-phenylene, 5-CONHEt-1,2-phenylene, 5-CONHPr-1,2-phenylene, 5-CONHBn-1,2-phenylene, 5-CONHCH 2 CONH 2 -1,2-phenylene, 5-CONHCH 2 CONHMe-1,2-phenylene, 5-CONHCH 2 CONHEt-1,2-phenylene, 5-CONH(—CH 2 -cyclopropyl)-1,2-phenylene, 5-CONH-(—CH 2 -cyclohexyl)-1,2-phenylene, 5-CONH-(—CH 2 -(4-COMe-Ph))-1,2-phenylene, 5-CONH(—CH 2 -2-oxazolyl)-1,2-phenylene, 5-CONH(—CH 2 -1,2,4-triazolyl)-1,2-phenylene, 5-CONH(—CH 2 -2-pyridyl)-1,2-phenylene, 5-CONH(—CH 2 -3-pyridyl)-1,2-phenylene, 5-CONH(—CH 2 -4-pyridyl)-1,2-phenylene, 5-CONH(—CH 2 -2-pyrimidinyl)-1,2-phenylene, 5-CONH(—CH 2 -3,4,5,6-tetrahydro-2-pyrimidinyl)-1,2-phenylene, 5-CONH(—CH 2 -(5-Me-2-pyrazinyl))-1,2-phenylene, 5-CONH(—CH 2 -2-thiazolyl)-1,2-phenylene, 5-CONH(—CH 2 -4-thiazolyl)-1,2-phenylene, 5-CONH(—CH 2 -5-thiazolyl)-1,2-phenylene, 5-CONH(—CH 2 -2-imidazolyl)-1,2-phenylene, 5-CONH(—CH 2 -4-imidazolyl)-1,2-phenylene, or 1,3-phenylene, wherein the attachment to L 2 is at carbon 1 of said phenylene groups;

B is 2-CO 2 H-phenyl, 2-CO 2 Et-phenyl, 2-CONH 2 -phenyl, 2-CONHSO 2 Me-phenyl, 2-SO 2 NH 2 -phenyl, 2-CH 2 OH-4-OMe-phenyl, 2-CO 2 H-3-Me-phenyl, 2-CO 2 H-4-Me-phenyl, 2-CO 2 H-5-Me-phenyl, 2-CO 2 Et-4-Me-phenyl, 2-CO 2 H-4-Cl-phenyl, 2-CO 2 Et-4-Cl-phenyl, 2-CO 2 H-4-OMe-phenyl, 2-CO 2 Et-4-OMe-phenyl, 2-CO 2 H-4-CONH 2 -phenyl, 2-CO 2 H-4,5-methylenedioxyphenyl, 3-CO 2 H-6-Me-2-pyridyl, 3-CO 2 H-5-Cl-2-pyridyl, 2-CO 2 H-1-pyrrolidinyl, 2-CO 2 Et-1-pyrrolidinyl, 1-Me-3-CO 2 H-4-pyrazolyl, 1-Me-5-CO 2 H-4-pyrazolyl, or 2-CO 2 H-1-piperidyl;

X5 is CH; and R 4 is H, Me, Et, Pr, i-Bu, Bn, —CONH 2 , —(CH 2 ) 2 CONH 2 , —(CH 2 ) 3 CONH 2 , —CH 2 -cyclopropyl, or —CH 2 -3-pyridyl.

5. A compound according to claim 4 , wherein:

B is 2-CO 2 H-phenyl, 2-CO 2 Et-phenyl, 2-CH 2 OH-4-OMe-phenyl, 2-CO 2 H-3-Me-phenyl, 2-CO 2 H-4-Me-phenyl, 2-CO 2 H-S -Me-phenyl, 2-CO 2 H-4-Cl-phenyl, 2-CO 2 H-4-OMe-phenyl, 2-CO 2 H-4-CONH 2 -phenyl, 2-CO 2 H-3,4-methylenedioxyphenyl, 3-CO 2 H-6-Me-2-pyridyl, 3-CO 2 H-5-Cl-2-pyridyl, 2-CO 2 H-1-pyrrolidinyl, 1-Me-3-CO 2 H-4-pyrazolyl, or 1-Me-5-CO 2 H-4-pyrazolyl.

6. A compound according to claim 3 , wherein:

A is 1,2-phenylene, 5-CONH(—CH 2 -3-pyridyl)-1,2-phenylene, 5-CONH(—CH 2 -(5-Me-2-pyrazinyl))-1,2-phenylene, or 5-CONH(—CH 2 -2-pyrimidinyl)-1,2-phenylene;

B is 2-CO 2 H-4-Me-phenyl, 2-CO 2 H-4-Cl-phenyl, 2-CO 2 H-4-OMe-phenyl, or 2-CO 2 Et-4-OMe-phenyl;

X 5 is N; and

R 4 is Et.

7. A compound according to claim 1 , wherein the compound is selected from:

2′-(6-carbamimidoyl-1H-indol-3-ylmethyl)-4-methoxy-biphenyl-2-carboxylic acid;

2′-(1-benzyl-6-carbamimidoyl-1H-indol-3-ylmethyl)-4-methoxy-biphenyl-2-carboxylic acid;

2′-(6-carbamimidoyl-1-ethyl-1H-indol-3-ylmethyl)-4-methoxy-biphenyl-2-carboxylic acid;

2′-(6-carbamimidoyl-1-isobutyl-1H-indol-3-ylmethyl)-4-methoxy-biphenyl-2-carboxylic acid;

2′-(6-carbamimidoyl-1-cyclopropylmethyl-1H-indol-3-ylmethyl)-4-methoxy-biphenyl-2-carboxylic acid;

2′-(6-carbamimidoyl-1-pyridin-3-ylmethyl-1H-indol-3-ylmethyl)-4-methoxy-biphenyl-2-carboxylic acid;

3′-(1-benzyl-6-carbamimidoyl-1H-indol-3-ylmethyl)-4-carbamoyl-biphenyl-2-carboxylic acid;

3′-(6-carbamimidoyl-1-ethyl-1H-indol-3-ylmethyl)-4-carbamoyl-biphenyl-2-carboxylic acid;

3′-(6-carbamimidoyl-1-ethyl-1H-indol-3-ylmethyl)-4-methoxy-biphenyl-2-carboxylic acid;

2′-(6-carbamimidoyl-1-methyl-1H-indol-3-ylmethyl)-4-methoxy-5-methylcarbamoyl-biphenyl-2-carboxylic acid;

2′-(6-carbamimidoyl-1-ethyl-1H-indol-3-ylmethyl)-4-methoxy-5′-methylcarbamoyl-biphenyl-2-carboxylic acid;

2′-(6-carbamimidoyl-1-ethyl-1H-indol-3-ylmethyl)-4-methoxy-5′-[(pyridine-2-ylmethyl)-carbamoyl]-biphenyl-2-carboxylic acid;

2′-(6-carbamimidoyl-1-methyl-1H-indol-3-ylmethyl)-4-methoxy-biphenyl-2-carboxylic acid;

2′-(6-carbamimidoyl-1-propyl-1H-indol-3-ylmethyl)-4-methoxy-biphenyl-2-carboxylic acid;

2′-(6-carbamimidoyl-1-ethyl-1H-indol-3-ylmethyl)-4-methoxy-5′-[(pyridin-3-ylmethyl)-carbamoyl]-biphenyl-2-carboxylic acid;

2′-(6-carbamimidoyl-1-ethyl-1H-indol-3-ylmethyl)-4-methoxy-5′-[(pyridin-4-ylmethyl)-carbamoyl]-biphenyl-2-carboxylic acid;

2′-(6-carbamimidoyl-1-ethyl-1H-indol-3-ylmethyl)-4-methyl-5′-methylcarbamoyl-biphenyl-2-carboxylic acid;

2′-(6-carbamimidoyl-1-ethyl-1H-indol-3-ylmethyl)-4-methyl-5′-[(pyridine-2-ylmethyl)-carbamoyl]-biphenyl-2-carboxylic acid;

2′-(6-carbamimidoyl-1-ethyl-1H-indol-3-ylmethyl)-biphenyl-2-carboxylic acid;

2′-(6-carbamimidoyl-1-ethyl-1H-indol-3-ylmethyl)-5′-ethylcarbamoyl-4-methoxy-biphenyl-2-carboxylic acids;

2′-(6-carbamimidoyl-1-ethyl-1H-indol-3-ylmethyl)-4-methoxy-5′-propylcarbamoyl-biphenyl-2-carboxylic acids;

2′-[6-carbamimidoyl-1-(2-carbamoyl-ethyl)-1H-indol-3-ylmethyl]-4-methoxy-biphenyl-2-carboxylic acids;

2′-[6-carbamimidoyl-1-(2-carbamoyl-propyl)-1H-indol-3-ylmethyl]-4-methoxy-biphenyl-2-carboxylic acids;

6-(6-carbamimidoyl-1-ethyl-1H-indol-3-ylmethyl)-2′-hydroxymethyl-4′-methoxy-biphenyl-3-carboxylic acid (pyridin-2-ylmethyl)-amide;

2′-(6-carbamimidoyl-1-ethyl-1H-indol-3-ylmethyl)-4-chloro-biphenyl-2-carboxylic acid;

5′-benzylcarbamoyl-2′-(6-carbamimidoyl-1-ethyl-1H-indol-3-ylmethyl)-4-methoxy-biphenyl-2-carboxylic acid;

2′-(6-carbamimidoyl-1-ethyl-1H-indol-3-ylmethyl)-5′-(ethylcarbamoylmethyl-carbamoyl)-4-methoxy-biphenyl-2-carboxylic acid;

2′-(6-carbamimidoyl-1-ethyl-1H-indol-3-ylmethyl)-4-methoxy-5′-[(oxazol-2-ylmethyl)-carbamoyl]-biphenyl-2-carboxylic acid;

2′-(6-carbamimidoyl-1-ethyl-1H-indol-3-ylmethyl)-4-methoxy-5′-[(5-methyl-pyrazin-2-ylmethyl)-carbamoyl]-biphenyl-2-carboxylic acids;

2′-(6-carbamimidoyl-1-ethyl-1H-indol-3-ylmethyl)-4-methoxy-5′-[(pyrimidin-2-ylmethyl)-carbamoyl]-biphenyl-2-carboxylic acid;

2′-(6-carbamimidoyl-1-ethyl-1H-indol-3-ylmethyl)-4-methoxy-5′-[(1,4,5,6-tetrahydro-pyrimidin-2-ylmethyl)-carbamoyl]-biphenyl-2-carboxylic acid;

2′-(6-carbamimidoyl-1-ethyl-1H-indol-3-ylmethyl)-4-methoxy-5′-[(1H-[1,2,4]triazol-3-ylmethyl)-carbamoyl]-biphenyl-2-carboxylic acid;

2′-(6-carbamimidoyl-1-ethyl-1H-indol-3-ylmethyl)-4-methyl-5′-[(1H-[1,2,4]triazol-3-ylmethyl)-carbamoyl]-biphenyl-2-carboxylic acid;

2′-(6-carbamimidoyl-1-ethyl-1H-indol-3-ylmethyl)-biphenyl-2-carboxylic acid ethyl ester;

2′-(6-carbamimidoyl-1-ethyl-1H-indol-3-ylmethyl)-5′-(ethylcarbamoylmethyl-carbamoyl)-4-methyl-biphenyl-2-carboxylic acid;

2′-(6-carbamimidoyl-1-ethyl-1H-indol-3-ylmethyl)-4-methyl-5′-[(pyridin-3-ylmethyl)-carbamoyl]-biphenyl-2-carboxylic acid;

5′-benzylcarbamoyl-2′-(6-carbamimidoyl-1-ethyl-1H-indol-3-ylmethyl)-4-methyl-biphenyl-2-carboxylic acid;

2′-(6-Carbamimidoyl-1-ethyl-1H-indol-3-ylmethyl)-4-methyl-5′-[(pyridin-4-ylmethyl)-carbamoyl]-biphenyl-2-carboxylic acid;

2′-(6-carbamimidoyl-1-ethyl-1H-indol-3-ylmethyl)-4-methyl-5′-[(5-methylpyrazin-2-ylmethyl)-carbamoyl]-biphenyl-2-carboxylic acid;

2′-(6-carbamimidoyl-1-ethyl-1H-indol-3-ylmethyl)-4-methyl-5′-propylcarbamoyl-biphenyl-2-carboxylic acid;

2′-(6-carbamimidoyl-1-ethyl-1H-indol-3-ylmethyl)-5′-(cyclopropylmethyl-carbamoyl)-4-methyl-biphenyl-2-carboxylic acid;

2′-(6-carbamimidoyl-1-ethyl-1H-indol-3-ylmethyl)-5′-(methylcarbamoylmethyl-carbamoyl)-4-methyl-biphenyl-2-carboxylic acid;

2′-(6-carbamimidoyl-1-ethyl-1H-indol-3-ylmethyl)-5′-(carbamoylmethyl-carbamoyl)-4-methoxy-biphenyl-2-carboxylic acid;

2′-(6-carbamimidoyl-1-ethyl-1H-indol-3-ylmethyl)-5′-(cyclohexylmethyl-carbamoyl)-4-methyl-biphenyl-2-carboxylic acid;

2′-(6-carbamimidoyl-1-ethyl-1H-indol-3-ylmethyl)-4-chloro-5′-[(5-methyl-pyrazin-2-ylmethyl)-carbamoyl]-biphenyl-2-carboxylic acid;

4-[2-(6-carbamimidoyl-1-ethyl-1H-indol-3-ylmethyl)-phenyl]-2-methyl-2H-pyrazole-3-carboxylic acid;

4-[2-(6-carbamimidoyl-1-ethyl-1H-indol-3-ylmethyl)-phenyl]-1-methyl-1H-pyrazole-3-carboxylic acid;

1-[2-(6-carbamimidoyl-1-ethyl-1H-indol-3-ylmethyl)-phenyl]-pyrrolidine-2-carboxylic acid;

2′-(6-carbamimidoyl-1-ethyl-1H-indol-3-ylmethyl)-4-methyl-5′-[(pyrimidin-2-ylmethyl)-carbamoyl]-biphenyl-2-carboxylic acid;

2′-(6-carbamimidoyl-1-ethyl-1H-indol-3-ylmethyl)-4-methyl-5′-[(1,4,5,6-tetrahydro-pyrimidin-2-ylmethyl)-carbamoyl]-biphenyl-2-carboxylic acid;

6′-(6-carbamimidoyl-1-ethyl-1H-indol-3-ylmethyl)-4-methyl-biphenyl-2,3 dicarboxylic acid;

2′-(6-carbamimidoyl-1-ethyl-1H-indol-3-ylmethyl)-4-methoxy-5′-[(thiazol-2-ylmethyl)-carbamoyl]-biphenyl-2-carboxylic acid;

2′-(6-carbamimidoyl-1-ethyl-1H-indol-3-ylmethyl)-4-methoxy-5′-[(thiazol-4-ylmethyl)-carbamoyl]-biphenyl-2-carboxylic acid;

2′-(6-carbamimidoyl-1-ethyl-1H-indol-3-ylmethyl)-4-methoxy-5′-[(thiazol-5-ylmethyl)-carbamoyl]-biphenyl-2-carboxylic acid;

2′-(6-carbamimidoyl-1-ethyl-1H-indol-3-ylmethyl)-5′-[(1H-imidazol-4-ylmethyl)-carbamoyl]-4-methoxy-biphenyl-2-carboxylic acid;

2′-(6-carbamimidoyl-1-ethyl-1H-indol-3-ylmethyl)-5′-[(1H-imidazol-2-ylmethyl)-carbamoyl]-4-methoxy-biphenyl-2-carboxylic acid;

2′-(6-carbamimidoyl-1-methanesulfonyl-1H-indol-3-ylmethyl)-4-methoxy-biphenyl-2-carboxylic acid;

2-[2-(6-carbamimidoyl-1-ethyl-1H-indol-3-ylmethyl)-phenyl]-5-chioro-nicotinic acid;

6-[2-(6-carbamimidoyl-1-ethyl-1H-indol-3-ylmethyl)-phenyl]-benzo[1,3]dioxole-5-carboxylic acid;

2-[2-(6-carbamimidoyl-1-ethyl-1H-indol-3-ylmethyl)-phenyl]-6-methyl-nicotinic acid;

2′-(6-carbamimidoyl-1-ethyl-1H-indol-3-ylmethyl)-3-methyl-biphenyl-2-carboxylic acid;

5′-(4-acetyl-benzylcarbamoyl)-2′-(6-carbamimidoyl-1-ethyl-1H-indol-3-ylmethyl)-4-methoxy-biphenyl-2-carboxylic acid;

2′-(6-carbamimidoyl-1-ethyl-1H-indol-3-ylmethyl)-5-methyl-biphenyl-2-carboxylic acid;

2-{2-(6-carbamimidoyl-1-ethyl-1H-indol-3-ylmethyl)-5-[(pyridin-2-ylmethyl)-carbamoyl]-phenoxy}-5-methyl-benzoic acid;

2′-(6-carbamimidoyl-1-ethyl-1H-indazol-3-ylmethyl)-4-methoxy-biphenyl-2-carboxylic acid;

2′-(6-carbamimidoyl-1-ethyl-1H-indazol-3-ylmethyl)-4-methoxy-biphenyl-2-carboxylic acid;

2′-(6-carbamimidoyl-1-ethyl-1H-indazol-3-ylmethyl)-4-methoxy-5′-[(pyridin-3-ylmethyl)-carbamoyl]-biphenyl-2-carboxylic acid;

2′-(6-carbamimidoyl-1-ethyl-1H-indazol-3-ylmethyl)-4-methyl-biphenyl-2-carboxylic acid;

2′-(6-carbamimidoyl-1-ethyl-1H-indazol-3-ylmethyl)-4-chloro-5′-[(pyridin-3-ylmethyl)-carbamoyl]-biphenyl-2-carboxylic acid;

2′-(6-carbamimidoyl-1-ethyl-1H-indazol-3-ylmethyl)-4-methyl-5′-[(pyridin-3-ylmethyl)-carbamoyl]-biphenyl-2-carboxylic acid;

2′-(6-carbamimidoyl-1-ethyl-1H-indazol-3-ylmethyl)-4-methoxy-5′-[(5-methyl-pyrazin-2-ylmethyl)-carbamoyl]-biphenyl-2-carboxylic acid;

2′-(6-carbamimidoyl-1-ethyl-1H-indazol-3-ylmethyl)-4-methyl-5′-[(5-methyl-pyrazin-2-ylmethyl)-carbamoyl]-biphenyl-2-carboxylic acid;

2′-(6-carbamimidoyl-1-ethyl-1H-indazol-3-ylmethyl)-4-methyl-5′-[(pyrimidin-2-ylmethyl)-carbamoyl]-biphenyl-2-carboxylic acid;

2′-(6-carbamimidoyl-1-ethyl-1H-indazol-3-ylmethyl)-4-methoxy-5′-[(pyrimidin-2-ylmethyl)-carbamoyl]-biphenyl-2-carboxylic acid;

2′-[1-ethyl-6-(N-hydroxycarbamimidoyl)-1H-indol-3-ylmethyl]-4-methoxy-5 [(pyridin-2-ylmethyl)-carbamoyl]-biphenyl-2-carboxylic acid;

2′-[1-ethyl-6-(N-hydroxycarbamimidoyl)-1H-indol-3-ylmethyl]-4-methyl-5′-[(5-methylpyrazin-2-ylmethyl)-carbamoyl]-biphenyl-2-carboxylic acid;

2′-[1-ethyl-6-(N-hydroxycarbamimidoyl)-1H-indol-3-ylmethyl]-4-methoxy-5′-[(3-triazolylmethyl)-carbamoyl]-biphenyl-2-carboxylic acid; and

2′-[1-ethyl-6-aminomethyl-1H-indol-3-ylmethyl]-4-methoxy-5′-[(pyridin-2-ylmethyl)-carbamoyl]-biphenyl-2-carboxylic acid;

or a stereoisomer or a pharmaceutically acceptable salt or a solvate thereof.

8. A pharmaceutical composition, comprising: a pharmaceutically acceptable carrier and a therapeutically effective amount of a compound of claim 1 .

9. A pharmaceutical composition, comprising: a pharmaceutically acceptable carrier and a therapeutically effective amount of a compound of claim 2 .

10. A pharmaceutical composition, comprising: a pharmaceutically acceptable carrier and a therapeutically effective amount of a compound of claim 3 .

11. A pharmaceutical composition, comprising: a pharmaceutically acceptable carrier and a therapeutically effective amount of a compound of claim 4 .

12. A pharmaceutical composition, comprising: a pharmaceutically acceptable carrier and a therapeutically effective amount of a compound of claim 5 .

13. A pharmaceutical composition, comprising: a pharmaceutically acceptable carrier and a therapeutically effective amount of a compound of claim 6 .

14. A pharmaceutical composition, comprising: a pharmaceutically acceptable carrier and a therapeutically effective amount of a compound of claim 7 .

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 26, 2005
From: SMALLHEER, JOANNE M.; CORTE, JAMES R.
To: BRISTOL-MYERS SQUIBB COMPANY
Reel/Frame 016277/0871 →
Continuity (3)
Provisional Application 6062748200 · Nov 12, 2004
Provisional Application 6056179200 · Apr 13, 2004
Related Publication 20050228000A1 · Oct 13, 2005